T-Stimu™ Recombinant EBNA3A Protein (CAR-TS-ZP3)

Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In contrast to peptides and unmodified proteins, T-Stimu™ proteins are processed and presented via functional antigen presenting cells (APC) through exogenous (MHC-II) and endogenous (MHC-I; cross-presentation) pathways, thus imitating natural infections.

In addition, the T-Stimu™ protein can produce more effective and HLA-independent stimulation of a broad subgroup of antigen-reactive effector cells (CD4 + and CD8 + T cells, NK and NKT-like cells).

Specifically, T-Stimu™ EBNA3A recombinant protein is processed through the exogenous and endogenous processing pathways of APC, and epitopes are loaded on MHC-II and MHC-1 molecules through cross-display, thereby inducing the activation of antigen-specific effector cells (including CD4 + T cells, CD8 + T cells, NK cells and NKT-like cells).

Specific Inquiry

Add to Cart

Specifications

Target
EBNA3A (Epstein-Barr nuclear antigen 3)

Organism
Human Epstein-Barr virus (EBV)

Application
• Activation of CMV reactive effector cell networks, including T helper cells (CD4 +), cytotoxic T cells (CD8 +), NK cells (CD56 +) and NKT-like cells (CD56 + CD3 +).
• Actively handled by APC to produce physiological and comprehensive stimulation.
• Stimulation and expansion of EBNA3A specific effector cells for subsequent activation detection
• Induction of cytokine production in immunoassays.

Content
Stock solution of EBNA3A (500 µl)

Capacity
For stimulation of up to 5 × 10*7cells

Format
Provided in a solution of sodium dihydrogen phosphate, sodium chloride and T-Stimu™ buffer.

Purity
> 90% as determined by SDS-PAGE analysis

Endotoxin Level
Low endotoxin

Storage
Store product protected from light at 2-8 °C

Shelf-Life
Expiry date is Lot specific (see label on vial)

Application Notes
Use EBNA3A at a final dilution of 1:75. To stimulate 2×105 PBMC, prepare 50 µl of 1:25 dilution of EBNA3A in the culture medium, and add 2 volumes of PBMC culture medium, the total volume of each well is 150 µl. If a higher concentration of antigen is required, use a dilution of at least 1:40 in the respective medium, because increased amounts of T-activation buffer may show cytotoxic effects.

Tag
Protein

Target

Target Introduction
Approximately 90% of the adult population is potentially infected with Epstein-Barr virus (EBV = human herpes virus 4 (HHV-4)). In most people, the primary infection is asymptomatic, but it can also cause infectious mononucleosis and may cause lymphoproliferative disease in patients with immunocompromised people.

Epstein-Barr nuclear antigen (EBNA3A) is an EBV nuclear oncogene, essential for EBV to make B cells effective and immortal, and is considered to play a vital role in the persistence of the virus in human hosts. EBNA3A is expressed in most EBV + B-cell lymphomas in lymphoproliferative disease (PTLD) after transplantation. Therefore, EBNA3A is a valuable antigen for studying cellular immunity against EBV and PTLD.

Customer Reviews and Q&As

There are currently no customer reviews or questions for T-Stimu™ Recombinant EBNA3A Protein (CAR-TS-ZP3). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

T-Stimu™ Recombinant EBNA3A Protein (CAR-TS-ZP3)

Specific Inquiry

Specifications

Target

Customer Reviews and Q&As

Related Products

TCR Viral Particles

TCR Vector Products

TCR Cell Products